[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341544-105":59,"doc-detail-341544-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","single-cell-analysis-of-treatment-resistant-prostate-cancer-implications-of-cell-state-changes-for-cell-surface-antigen-targeted-therapies","Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies","","Single-cell analysis clarifies how lineage plasticity reshapes cell surface antigen expression in treatment-resistant prostate cancer. The study profiles 21 human tumor biopsies and two genetically engineered mouse models, plus tissue microarray data from 131 samples, revealing greater phenotypic heterogeneity in castrate-resistant prostate adenocarcinoma and neuroendocrine prostate cancer than expected. It shows antigen-targeted molecules (PSMA, STEAP1/2, TROP2, CEACAM5, DLL3) vary across gene-regulatory networks, and NEPC aligns with small-cell lung cancer networks, suggesting conserved pathways. Despite extreme transcriptional heterogeneity that may limit therapeutic durability, the work identifies signatures to support patient selection in antigen-directed clinical trials.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/single-cell-analysis-of-treatment-resistant-prostate-cancer-implications-of-cell-state-changes-for-cell-surface-antigen-targeted-therapies/341544/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/single-cell-analysis-of-treatment-resistant-prostate-cancer-implications-of-cell-state-changes-for-cell-surface-antigen-targeted-therapies/341544.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are cell surface antigens critical for antigen-directed therapies in prostate cancer?","Question",{"text":112,"@type":113},"ADC, radioligand, bispecific T cell engager, and CAR-T approaches rely on sufficient target antigen expression on cancer cells to achieve tumor reduction or elimination while maintaining an acceptable therapeutic index.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the study find about lineage plasticity in castrate-resistant prostate adenocarcinoma and NEPC?",{"text":117,"@type":113},"It finds higher-than-expected phenotypic heterogeneity in castrate-resistant prostate adenocarcinoma and neuroendocrine prostate cancer, including variable expression of therapeutically targeted cell surface molecules.",{"name":119,"@type":110,"acceptedAnswer":120},"How might the reported gene regulatory networks help clinical development?",{"text":121,"@type":113},"Gene regulatory network-defined cell states correlate with clinically relevant cell surface antigen expression and can provide additional diagnostic precision, potentially enabling trial designs that better select patients across tumor types.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341544,1790172667,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","RESEARCH ARTICLE  \nMEDICAL SCIENCES  \n OPEN ACCESS  \nSingle-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen– targeted therapies  \nSamir Zaidia, b, Jooyoung Parkc , Joseph M. Chana,d, Martine P. Roudiere, Jimmy L. Zhaof, Anuradha Gopalang, Kristine M. Wadoskyh, Radhika A. Pateli,j, Erolcan Sayari,j, Wouter R. Karthausk, D. Henry Katesa, Ojasvi Chaudharyd, Tianhao Xud, Ignas Masilionisd, Linas Mazutisd, Ronan Chalignéd, Aleksandar Obradovicl, Irina Linkovg, Afsar Barlasm, Achim A. Jungbluthg, Natasha Rekhtmang, Joachim Silberg, Katia Manova-Todorovam, Philip A. Watsonn, Lawrence D. Trueo, Colm Morrisseye, Howard I. Scherb, Dana E. Rathkopfb, Michael J. Morrisb , David W. Goodrichh, Jungmin Choic, p, Peter S. Nelsoni,j,  \nMichael C. Haffneri,j,o,1,2, and Charles L. Sawyersa,q,1,2 Affiliations are included on p. 9.  \nContributed by Charles L. Sawyers; received January 2, 2024; accepted May 9, 2024; reviewed by Gert Attard and Alvaro Aytes Meneses  \nTargeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules, varies in the process of lineage plasticity, wherein tumor cells alter their identity and acquire new oncogenic properties. A notable example of lineage plasticity is the transformation of prostate adenocarcinoma (PRAD) to neuroendocrine prostate cancer (NEPC)—a growing resistance mechanism that results in the loss of responsiveness to androgen blockade and portends dismal patient survival. To understand how lineage markers vary across the evolution of lineage plasticity in prostate cancer, we applied single-cell analyses to 21 human prostate tumor biopsies and two genetically engineered mouse models, together with tissue microarray analysis on 131 tumor samples. Not only did we observe a higher degree of phenotypic heterogeneity in castrate-resistant PRAD and NEPC than previously anticipated but also found that the expression of molecules targeted therapeutically, namely PSMA, STEAP1, STEAP2, TROP2, CEACAM5, and DLL3, varied within a subset of gene-regulatory networks (GRNs). We also noted that NEPC and small cell lung cancer subtypes shared a set of GRNs, indicative of conserved biologic pathways that may be exploited therapeutically across tumor types. While this extreme level of transcriptional heterogeneity, particularly in cell surface marker expression, may mitigate the durability of clinical responses to current and future antigen-directed therapies, its delineation may yield signatures for patientselection in clinical trials, potentially across distinct cancer types.  \nlineage plasticity | cell states | heterogeneity | epithelial maligancies  \nIn recent years, there has been a remarkable increase in the clinical development of antibody drug conjugates (ADCs), radioligand therapies (RLTs), bispecific T cell engagers, and chimeric antigen receptor-expressing T cells (CAR–Ts), all of which are designed to target cell surface antigens expressed on cancer cells (1–5). ADCs selectively deliver potent chemotherapeutic toxins and RLTs deliver lethal doses of radiation, whereas bispecificsand CAR–Ts leverage the immune system for tumor killing. All four approaches require expression of the target antigen on cancer cells (to ensure tumor reduction/elimination), and the level of expression often must be greater than that in normal tissue to achieve an acceptable therapeutic index (6, 7) . Consequently, clinical trials must be designed in a manner that ensures the selection of patients that meet these criteria, often through a companion diagnostic. The development of a radiotheranostic for castrate-resistant prostate cancer (CRPC) is a particularly noteworthy example, wherein a small molecule (PSMA-617) targeting prostate-specific membrane antigen (PSMA) is combined with a therapeutic ra","cbCaip4OFoN7Ovvl","https://ap.wps.com/l/cbCaip4OFoN7Ovvl","pdf",14446308,"English","# Significance\n## Antibody and radioligand therapy requirements\n## Single-cell profiling strategy and evidence\n## Implications for patient selection and therapy durability","[{\"question\":\"Why are cell surface antigens critical for antigen-directed therapies in prostate cancer?\",\"answer\":\"ADC, radioligand, bispecific T cell engager, and CAR-T approaches rely on sufficient target antigen expression on cancer cells to achieve tumor reduction or elimination while maintaining an acceptable therapeutic index.\"},{\"question\":\"What does the study find about lineage plasticity in castrate-resistant prostate adenocarcinoma and NEPC?\",\"answer\":\"It finds higher-than-expected phenotypic heterogeneity in castrate-resistant prostate adenocarcinoma and neuroendocrine prostate cancer, including variable expression of therapeutically targeted cell surface molecules.\"},{\"question\":\"How might the reported gene regulatory networks help clinical development?\",\"answer\":\"Gene regulatory network-defined cell states correlate with clinically relevant cell surface antigen expression and can provide additional diagnostic precision, potentially enabling trial designs that better select patients across tumor types.\"}]","Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies | PDF",1790042473,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd6be706b093623807ccab264b7b31ec.webp",983,1316,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b9c485ee069a1372f9528d2285456b31.webp",982,1315,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23ab0aaa5046e49b3811a7409fef42d5.webp",981,1313,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/008939591b01f1442f67ed9965ba1aa2.webp",980,1312]